UroGen Pharma Files 8-K for Financial Updates
Ticker: URGN · Form: 8-K · Filed: 2024-03-14T00:00:00.000Z
Sentiment: neutral
Topics: financial-reporting, 8-K
TL;DR
UroGen Pharma dropped an 8-K on March 14th detailing financial results and exhibits.
AI Summary
UroGen Pharma Ltd. filed an 8-K on March 14, 2024, to report on its results of operations and financial condition, as well as to file financial statements and exhibits. The filing provides updates on the company's financial performance and operational status.
Why It Matters
This filing provides crucial information for investors and stakeholders regarding UroGen Pharma's financial health and operational performance.
Risk Assessment
Risk Level: low — This is a routine financial filing and does not indicate any immediate material changes or risks.
Key Players & Entities
- UroGen Pharma Ltd. (company) — Registrant
- March 14, 2024 (date) — Filing Date
FAQ
What is the primary purpose of this 8-K filing by UroGen Pharma Ltd.?
The primary purpose is to report on the company's Results of Operations and Financial Condition, and to file Financial Statements and Exhibits.
On what date was this 8-K filing made?
The filing was made on March 14, 2024.
What is UroGen Pharma Ltd.'s state of incorporation?
UroGen Pharma Ltd. is incorporated in Israel.
What is the Commission File Number for UroGen Pharma Ltd.?
The Commission File Number is 001-38079.
What is the address of UroGen Pharma Ltd.'s principal executive offices?
The address is 400 Alexander Park Drive, 4th Floor Princeton, New Jersey 08540.
Filing Stats: 500 words · 2 min read · ~2 pages · Grade level 11.2 · Accepted 2024-03-14 08:16:01
Filing Documents
- d675566d8k.htm (8-K) — 25KB
- d675566dex991.htm (EX-99.1) — 80KB
- 0001193125-24-067432.txt ( ) — 240KB
- urgn-20240314.xsd (EX-101.SCH) — 3KB
- urgn-20240314_lab.xml (EX-101.LAB) — 18KB
- urgn-20240314_pre.xml (EX-101.PRE) — 11KB
- d675566d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibit Number Description 99.1 Press Release dated March 14, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: March 14, 2024 UROGEN PHARMA LTD. By: /s/ Don Kim Don Kim Chief Financial Officer